TY - JOUR
T1 - Rapid extracellular vesicle surface decoration with targeting moieties based on a fluorescein binding single chain variable fragment snorkel
AU - Roefs, Marieke Theodora
AU - Gamauf, Johanna
AU - Kroenigsberger, Barbara
AU - Brancolini, Alessia
AU - Traxlmayr, Michael W.
AU - Arcalis, Elsa
AU - Jacak, Jaroslaw
AU - van Mechelen, Marcelle
AU - Prieels, Jean Paul
AU - Grillari-Voglauer, Regina
AU - Grillari, Johannes
AU - Bobbili, Madhusudhan Reddy
N1 - Publisher Copyright:
© 2025 The Author(s)
PY - 2026/2/10
Y1 - 2026/2/10
N2 - Extracellular vesicles (EVs) are cell-derived nanovesicles with promising potential for drug delivery due to their low toxicity and immunogenicity. However, their clinical application is limited by poor targeting to sites of interest. Existing strategies to engineer targeted EVs often require genetic donor cell modification for each specific target, making the process time-consuming and costly. To overcome this, we developed a versatile targeting platform using the fluorescein-specific single-chain variable fragment (scFv) 4 M5.3, integrated into a CD81-based Snorkel-tag construct for surface display on EVs. A C-terminal HA-tag, separated by a PreScission protease (PS) site, allows selective purification of targeted EVs and removal of unbound targeting moieties. This design enables functionalization of EVs with any fluorescein-conjugated targeting molecule. We tested various construct modifications (cMyc, FLAG, PS-HA), which showed differing expression levels and FITC-antibody binding by HEK293 cells and their EVs. As proof of concept, we generated EVs targeting human HER2 and mouse CCR2 by capturing FITC-labeled antibodies, which bound specifically to HER2+ NCI-N87 and CCR2+ RAW264.7 cells. The technology was also successfully applied to transmembrane protein CD9 and WJ-MSC/TERT273-derived EVs. In summary, we present a robust, adaptable method for generating EVs with customizable targeting, enabling high-throughput target screening and accelerating the development of EV-based therapeutics.
AB - Extracellular vesicles (EVs) are cell-derived nanovesicles with promising potential for drug delivery due to their low toxicity and immunogenicity. However, their clinical application is limited by poor targeting to sites of interest. Existing strategies to engineer targeted EVs often require genetic donor cell modification for each specific target, making the process time-consuming and costly. To overcome this, we developed a versatile targeting platform using the fluorescein-specific single-chain variable fragment (scFv) 4 M5.3, integrated into a CD81-based Snorkel-tag construct for surface display on EVs. A C-terminal HA-tag, separated by a PreScission protease (PS) site, allows selective purification of targeted EVs and removal of unbound targeting moieties. This design enables functionalization of EVs with any fluorescein-conjugated targeting molecule. We tested various construct modifications (cMyc, FLAG, PS-HA), which showed differing expression levels and FITC-antibody binding by HEK293 cells and their EVs. As proof of concept, we generated EVs targeting human HER2 and mouse CCR2 by capturing FITC-labeled antibodies, which bound specifically to HER2+ NCI-N87 and CCR2+ RAW264.7 cells. The technology was also successfully applied to transmembrane protein CD9 and WJ-MSC/TERT273-derived EVs. In summary, we present a robust, adaptable method for generating EVs with customizable targeting, enabling high-throughput target screening and accelerating the development of EV-based therapeutics.
KW - Engineering
KW - Extracellular vesicles (EVs)
KW - HER2
KW - Targeting
KW - WJ-MSC/TERT273, snorkel-tag
KW - Humans
KW - Extracellular Vesicles/metabolism
KW - Fluorescein/chemistry
KW - Drug Delivery Systems
KW - Animals
KW - Single-Chain Antibodies/chemistry
KW - HEK293 Cells
KW - Mice
UR - https://www.scopus.com/pages/publications/105025778680
U2 - 10.1016/j.jconrel.2025.114558
DO - 10.1016/j.jconrel.2025.114558
M3 - Article
C2 - 41421744
AN - SCOPUS:105025778680
SN - 0168-3659
VL - 390
SP - 114558
JO - Journal of Controlled Release
JF - Journal of Controlled Release
M1 - 114558
ER -